{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Takeda Pharmaceutical will pay $2.4 billion to settle thousands of lawsuits contending that company's Actos diabetes drug caused bladder cancer; roughly 9,000 bladder cancer claims are pending against company.", "type_of_material": "News", "word_count": "656", "lead_paragraph": "Nearly 9,000 bladder cancer claims are pending against Takeda, which was accused of concealing the cancer risk of the big-selling medication.", "pub_date": "2015-04-29T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos", "print_headline": "Takeda to Pay $2.4 Billion to Settle Suits Over Drug\u2019s Cancer Risk"}, "snippet": "Nearly 9,000 bladder cancer claims are pending against Takeda, which was accused of concealing the cancer risk of the big-selling medication.", "multimedia": [{"height": 126, "url": "images/2015/04/29/business/29DRUG/29DRUG-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/04/29/business/29DRUG/29DRUG-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/04/29/business/29DRUG/29DRUG-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/04/29/business/29DRUG/29DRUG-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/04/29/business/29DRUG/29DRUG-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/04/29/business/29DRUG/29DRUG-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/04/29/business/takeda-agrees-to-pay-2-4-billion-to-settle-suits-over-cancer-risk-of-actos.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Takeda Pharmaceutical", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Liability for Products", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Bladder Cancer", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Diabetes", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Suits and Litigation (Civil)", "name": "subject"}], "blog": [], "_id": "55400dfd38f0d877377da13e", "source": "The New York Times"}